Navigation Links
FDA Panel Recommends Approval of SyntheMed's REPEL-CV(R) Adhesion Barrier for Pediatric Patients
Date:9/22/2007

ISELIN, N.J., Sept. 20 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products, announced today that the Circulatory System Devices Advisory Panel of the US Food and Drug Administration (FDA) recommended approval of REPEL-CV(R) Adhesion Barrier for use in pediatric patients (21 and younger) who are likely to need secondary open heart surgery. The panel also recommended the development of additional safety data as a basis for expanding the indicated use to include adult patients. Dr. Eli Pines, the Company's Vice President of Research stated, "We are pleased with the panel's recommendation to approve REPEL-CV and we look forward to discussions with the FDA on securing approval to market REPEL-CV for the initial indication. We will also immediately seek FDA approval to initiate the adult clinical study."

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surround tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure. There are approximately 500,000 open heart surgeries performed annually in the United States, and another 350,000 procedures estimated throughout the European Union. In both markets, approximately 15-20 percent of these surgeries are secondary procedures.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions (scar tissue) that form between the surface of the heart and opposing tissue surfaces following the surgical procedure. REPEL-CV is designed to provide the therapeutic benefit and then degrade so that it is cleared from the body. A CE Mark was granted in August 2006 and REPEL-CV is marketed through a network of independent distributors in international markets. REPEL-CV represents the first in a series of anti-adhesion products under development that are based on the Company's proprietary polymer technology.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion and drug delivery products. The Company is primarily focused on the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technology.

Statements in this Press Release that are not statements of historical fact, including statements regarding indications of the timing or ability to achieve regulatory approval and market launch for REPEL-CV or the potential market size for REPEL-CV, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the Company's efforts to obtain and maintain required FDA and other regulatory approvals; (ii) potential inability to secure funding as and when needed to support the Company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006 for a description of these, as well as other, risks and uncertainties.


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Panel suggests selling allergy drugs OTC
2. FDA panel refuses anti-viral cold remedy
3. Panel to Help Combat HIV/AIDS In Asia-Pacific Region
4. Expert panel confident of making AIIMS fully autonomous
5. Anti-Quota Stir: Resident Docs Demand Experts Panel
6. Circumcision Studies to Continue Says Health Panel
7. Breast Cancer Review Panel Adds Two Experts
8. Shingles Vaccine For Older People - Panel Recommendation
9. Complaints Against US Federal lab Over-ruled by Panel
10. E.U. Panel Backs Novartis Mock-up Pandemic Flu Vaccine
11. Generic Biologics – U.S Panel Hearing Draws Mixed Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... appointment of Mike Finnegan to the position of Executive Vice President, Sales and ... in healthcare technology, telehealth and medical device sales leadership. He has received industry ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... many of the health care industry’s hospitals and provider groups, has announced that ... for select customers. Parasail Health is a San Francisco health-finance startup that has ...
(Date:6/27/2017)... ... June 27, 2017 , ... A January 18th article ... reach a staggering $6.81 billion by the year 2024 according to a new report. ... rate than those made from titanium. Los Angeles area clinic Beverly Hills Periodontics & ...
(Date:6/27/2017)... ... June 27, 2017 , ... Atmosera , ... Atmosera Managed Azure Services . The trusted, transparent, and secure solution for the ... growing customer base. Atmosera’s next generation services include integrated capabilities for public, private, ...
(Date:6/27/2017)... ... June 27, 2017 , ... Today, June 27th is ... PTSD. Yet less than 20% will receive adequate care due to lack of effective ... receive any care at all. And left untreated, veterans are at an increased risk ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... -- Exactly 50 years ago today, the Monterey Pop Festival opened ... the San Francisco "Summer of Love."  To celebrate the anniversary, ... in strategic market research portals that it will begin delivering ... Northern Light,s "Summer of Love (For Our Customers)."  ... ...
(Date:6/14/2017)... , June 14, 2017  In 2016, Embodied ... Startups pitch competition and came away with $25,000 ... is described by Forbes as "entering the life of ... Association as teaching "empathy to medical professionals in an ... was recently named a finalist for the Department of ...
(Date:6/11/2017)...  Eli Lilly and Company (NYSE: LLY ) ... of galcanezumab, an investigational treatment for the prevention of ... key secondary endpoints for galcanezumab compared to placebo at ... EVOLVE-2 and REGAIN) will be presented today at the ... Boston . "The detailed ...
Breaking Medicine Technology: